The Director of Finance will develop, assess and maintain secure, effective and innovative finance and grants functions at BHI. As a direct report to the President & CEO, the Director of Finance influences the BHI organization through strategic decision making, which influences BHI operations decisions as BHI continues to add capacity. This position oversees and is supported by the Manager, Human Resources & Operations. The position is summarized as follows:
FINANCE
Analyze and present financial reports in an accurate and timely manner; present consolidated quarterly financial reports at Board of Directors meetings; oversee all financial, program and grants accounting.
Coordinate and lead the annual audit process, liaise with external auditors and the treasurer of the Board of Directors; assess any changes necessary.
Lead annual budgeting and planning process for parent organization and subsidiary; administer and review all financial plans and budgets; monitor progress and changes and keep Chief Executive Officer abreast of the organization’s financial status.
Manage organizational cash flow and forecasting.
Work with BHI’s accounting firm to file annual tax returns.
Ensure that the accounts receivable collection schedule is adhered to and that financial data and cash flow are steady and support operational requirements; update collection schedule based on changes in cash flow; and thank charitable contributors who have made payments.
Ensure that organizational financial obligations (i.e. salaries payable, invoices payable) are met in a timely
manner and that financial commitments fall in line with cash flow plan.
Update and implement accounting practices; improve the finance department’s overall policy and procedure manual.
Effectively communicate and present critical financial matters to the CEO and Board of Directors.
To apply, please send your resume, cover letter, and salary requirements to Amanda Hague at ahague@biohealthinnovation.org. No recruiter calls will be accepted.
Senseonics is set to raise $41 million to support the anticipated commercialization of implantable continuous glucose monitoring (CGM) system Eversense. The fundraising attracted the support of major existing shareholders New Enterprise Associates (NEA) and Roche.
This is the third Challenge Project which the two organisations have run together.
UTC Cambridge students attended weekly sessions with scientists and business professionals from the MedImmune team to learn about many aspects of a medicine’s discovery and development, including scientific research, manufacturing and regulation. In addition to visiting MedImmune’s state-of-the-art laboratories at Granta Park, students also attended workshops, classes and practical sessions held at UTC Cambridge’s purpose-designed building at the Cambridge Biomedical Campus. In addition to gaining exposure to scientific research disciplines, students focused on practical and operational matters such as the importance of team work and collaboration, as well as wider concerns facing patients, government and industry on a global scale.
Saluda Medical has raised $40 million in a round led by a GlaxoSmithKline VC fund. The series D gives Saluda the means to take its spinal cord stimulation (SCS) device through a pivotal trial in the U.S. while commercializing it in Europe and its home country, Australia.
Writing on trends, I frequently profile tech companies that use trends to outperform competitors. But using trends is not restricted to tech companies.
By following trends, since 1998 Alexandria Real Estate Equities has tripled the performance of the NASDAQ, quadrupled returns of the S&P 500, and quintupled the Russell 2000. Alexandria has even outperformed technology stalwart Microsoft, and investment guru Berkshire Hathaway by 230%.
Event will include music, lawn games, hors d’oeuvres, drinks.
MedImmune fully supports and abides by the PhRMA Code on Interactions with Healthcare Professionals. MedImmune cannot accommodate or pay for the cost of a spouse or other guest of a healthcare professional. As such, this event is open to invitees only. If you are a prescriber and/or a Federal, State, or Institution employee, you may be subject to laws, regulations, or rules which prohibit, limit, or require the public disclosure of gifts, meals, or items of value you may receive. We ask that you comply with any such laws, regulations, or rules that govern your receipt of gifts, meals, or items of value. Please bring your State License Number (SLN) and National Provider Identifier (NPI) to the event. These will be used for reporting purposes where required by state and federal law (OPEN Payments). You may look up your NPI and SLN at http://www.npinumberlookup.org/.
TP Therapeutics, Inc., a clinical-stage biopharmaceutical company focusing on addressing oncology drug resistance, announced today that the company raised $45 million in a Series C financing round. The round was co-led by Lilly Asia Ventures (LAV), OrbiMed Advisors, LLC, and S.R. One, Limited, and joined by existing investors Cormorant Asset Management and SV Tech Ventures. In conjunction with the financing, Carl L. Gordon, Ph.D., CFA, General Partner at OrbiMed, Hongbo Lu, Ph.D., Partner at LAV, and Simeon J. George, M.D., Partner at S.R. One, joined the company’s Board of Directors.
GlaxoSmithKline, once the largest real estate owner in Research Triangle Park, has sold what’s left of its once-sprawling RTP campus and will lease back a small portion of the property where 3,000 employees and contractors work.
The deal, involving 20 buildings, was announced late Friday by Los Angeles-based Parmer Innovation Centers, which purchased the property, and by CBRE, a Los Angeles-based real-estate advisory that represented GSK in the real estate sale. The sale price was not disclosed.
This inaugural event will showcase technologies being developed at the National Cancer Institute (NCI) in Bethesda and Frederick, and Frederick National Laboratory for Cancer Research (FNLCR) to encourage startup formation, technology licensing, and collaborations. It will introduce the local scientific community to the regional technology development stakeholders and highlight available resources.
Prospective investors, established companies, interested stakeholders, and those looking to commercialize technologies are invited and encouraged to attend. The day will feature short technology summaries by NCI and FNLCR innovators, as well as presentations from regional stakeholders involved with technology development and commercialization. An interactive poster session by innovators and technology ambassadors will concurrently occur.
The purpose of the administrative supplement is to provide support for NIH-funded investigators to participate in an entrepreneurship training course, the Concept to Clinic: Commercializing Innovation (C3i) Program. The C3i Program is designed to provide medical device innovators with the specialized business frameworks and essential tools for successful translation of biomedical technologies from the lab (concept) to the market (clinic). Through this program, the NIH fosters the development and commercialization of early-stage biomedical technologies by engaging investigators who are interested in better understanding the value of their innovation in addressing an unmet market need. The curriculum and customized mentoring provided by the C3i Program are intended to guide investigators as they assess the commercial viability and potential business opportunity for their innovation. Prospective applicants are strongly encouraged to contact NIH Scientific/Research staff for more information about the program before applying.
Check-out our dynamic line-up of speakers and their panels:
RISE OF MEDICAL CENTERS AS “INNOVATION DISTRICTS”
Panelists will discuss the new real estate drivers around the medical campus planning and the physical design and programs that will change the way healthcare research and practice are delivered. Panel speakers include:
Inova Health System and University of Virginia are kicking off their new partnership with $450,000 in seed money to fund nine joint research projects geared toward better predicting, preventing and treating disease.
Senator Bill Frist, MD, is among the country’s most important healthcare leaders. He is a partner at Nashville-based Frist Cressey Ventures, a heart/lung transplant surgeon and a serial entrepreneur. He’s also the former US Senate Majority Leader and has had a ring-side seat at the development of Nashville’s healthcare startup scene, which is now one of the most mature in the country.
University of Pittsburgh Chancellor Patrick Gallagher’s efforts to hotwire the region’s fledgling life sciences industry is getting a spark from a new seed capital fund targeted to helping develop new medications.
The Pittsburgh Revolution Fund is soliciting $200 million, which will be made available in the form of investments in drug research teams with the idea of spinning out companies, said Bill Newlin, chairman, Newlin Investment Co., a seed-stage investment firm in Sewickley.
ABOUT THE USDD: Every six months, the University Startups Demo Day engages with universities to accept 200 of their best university startups to be scored by a Corporate Selection Committee consisting of Fortune 500 companies. These double-curated startups by academia and industry represent the very top startups coming out of American universities that are industry aligned. The University IP Into University Startups (IP2Startups) program provide Fortune 500 companies an effective way to identify university technologies that correspond to business unit needs that can be licensed or commercialized by university startups. Our Investor Roadshow program provides funding for select Demo Day companies that develop towards corporate milestones over 2-7 years from the IP2Start and Demo Day programs.
IP2Startups and USDD Corporate Selection Committee Pool Includes: Air Products – Specialized Chemicals | Astra Zeneca – Pharmaceuticals | Barilla – Food Processing | BASF – Diversified Chemicals | BMW – Auto & Truck Manufacturers | Dassault Systemes – Software & Programming | DuPont – Chemicals | Eastman Chemical Company – Specialized Chemicals | Eli Lilly and Co. – Pharmaceuticals | Evonik – Specialty chemicals | Faurecia – Automotive parts manufacturing | GlaxoSmithKline – Pharmaceuticals | Hyundai – Auto & Truck Manufacturers | IBM – Computer Services | Johnson & Johnson – Medical Equipment & Supplies | Janssen Pharmaceutical Companies of J&J – Pharmaceuticals | M Ventures (Merck KGaA) – Healthcare, Life Sciences, Performance Materials | Medline – Medical and Surgical Supplies | Pepsico – Beverages and Foods | Pfizer – Pharmaceuticals | SABIC – Chemicals | Saint-Gobain – Construction Materials | Sanofi – Pharmaceuticals | Schlumberger – Oil Services & Equipment | Sony – Consumer Electronics | The J.M. Smucker Company – Food Processing | Unilever – Household/Personal Care | Western Digital Capital – Computer Storage Devices
Pappas Capital, a life science venture capital firm, announced today that its new fund, Pappas Ventures V, recently invested in OrphoMed, a clinical stage company that is developing best-in-class therapies for treatment of inadequately-controlled gastrointestinal disorders. The investment in OrphoMed is the first investment by the new Pappas Ventures fund.
The information contained in this website and newsletters is for general information purposes only. The information is provided by BioHealth Innovation via its newsletters, but not written or endorsed in any way by BioHealth Innovation unless otherwise noted. While we endeavor to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
